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Abstract The rate of biosynthesis and turnover of the
plasma protein ﬁbrinogen is a marker of metabolic sig-
naling in aging and disease. The rate in the young normal
human subject of 0.260 mg/ml/24 h increases to 0.378 in
older normal subjects and to 0.466 in age matched coro-
nary thrombosis patients measured by endogenous labeling
of ﬁbrinogen with L-glutamic acid-C14. The increased rate
of ﬁbrinogen turnover has been traced to generation of
ﬁbrin by labeling the polymers with glycine C14 ethyl
esters in the presence of activated ﬁbrin stabilizing factor.
Circulating ﬁbrin increased 520% above normal in ische-
mic thrombotic cerebrovascular disease. Long chain satu-
rated free fatty acids (FFA) exercise not only primary
control over incorporation of Cl4 labeled amino acids into
the ﬁbrinogen structure but also activate the cascade
sequence of reactions which convert ﬁbrinogen into
occlusive ﬁbrin polymers. FFA are normally bound and
transported by plasma albumin to mitochondrial sites of
energy metabolism. Albumin synthesis declines with aging.
This decline is associated with increased plasma levels of
FFA resulting in an increase in the plasma FFA/albumin
ratio. Correction of this ratio in vitro by restoration of a
normal FFA/albumin ratio restores a normal level of
ﬁbrinogen synthesis by human hepatocytes.
Keywords Fibrinogen  Fatty acids  Fibrin  Albumin 
Thrombosis  Risk factor  Metabolic signaling
Introduction
Increased plasma ﬁbrinogen in coronary heart disease has
been known since 1959 (Schram and Pilgeram 1959; Pil-
geram 1961, 1993) and identiﬁed as a risk factor for future
cardiovascular events in prospective long term studies of
apparently healthy subjects (Stone and Thorp 1985; Meade
et al. 1986; Kannel et al. 1987; Yarnell et al. 1991; Burr
et al. 1992) and in patients with coronary heart disease
(Heinrich et al. 1994; Benderly et al. 1996). Deteriorating
prognosis in patients with unstable coronary heart disease
is associated with increased ﬁbrinogen levels (Toss et al.
1997). Early signs of occlusive vascular disease in patients
who are asymptomatic have been associated with increased
ﬁbrinogen levels (Levenson et al. 1995; Tracy et al. 1995).
Monitoring of the plasma level of ﬁbrinogen in high risk
patients, who had experienced previous ischemic events,
found the plasma level of ﬁbrinogen to progressively
increase prior to the clinically overt ictus of coronary
thrombosis and thrombotic stroke (Pilgeram 1984).
These reports present a crucial question on the rele-
vance of this increase to thrombogenesis, coronary heart
disease, thrombotic stroke and potential preventive ther-
apy. Was the increased plasma level of ﬁbrinogen due to
increased synthesis and turnover into occlusive ﬁbrin or
due to depressed utilization of ﬁbrinogen as a physio-
logical corrective action? To answer this question, a
technology was developed based on endogenous labeling
of ﬁbrinogen with L-glutamic acid-C14 which enabled
measuring the in vivo rate of biosynthesis and turnover of
ﬁbrinogen. This research demonstrated the increase in the
plasma level of ﬁbrinogen to be due to increased syn-
thesis and turnover. The rate in the young normal human
subject of 0.260 mg/ml/24 h increased to 0.378 in older
normal subjects and to 0.466 in age matched patients
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This increased rate of synthesis and turnover of ﬁbrin-
ogen was traced to generation of ﬁbrin by development of a
technology which labeled circulating ﬁbrin molecules with
glycine-C14 ethyl esters in the presence of activated ﬁbrin
stabilizing factor. Circulating ﬁbrin was found to increase
520% (P\0.001) above normal in patients who had
incurred and recovered from ischemic thrombotic cere-
brovascular disease (Pilgeram et al. 1973; Pilgeram 1973).
A screening study on the effect of multiple factors on
the in vitro rate of synthesis of ﬁbrinogen in hepatocytes,
measured by the incorporation of C14 labeled amino acids
into the protein structure, identiﬁed long chain saturated
fatty acids as the primary factor (Pilgeram and Pickart
1968). Di-nitro phenol, a speciﬁc inhibitor of protein syn-
thesis, prevented this action of fatty acids thus establishing
speciﬁcity at the level of protein synthesis. In designing a
study aimed at determining if dysfunctional fatty acid
metabolism was responsible for increased synthesis of
ﬁbrinogen in thrombosis, focus was aimed at the plasma
protein albumin because albumin had been identiﬁed as the
obligatory co-factor which accepts free fatty acids (FFA)
released during corrective clearing of alimentary lipemia
by lipoprotein lipase in patients who had experienced
coronary thrombosis (Pilgeram 1958; Pilgeram et al. 1964).
Although the plasma level of FFA is inﬂuenced by a
number of factors, including dietary and mobilization from
adipose tissue fat stores, the primary factor was considered
to be the degree to which FFA is bound and transported by
albumin. Focus was therefore directed to determining
whether the plasma level of FFA could be correlated with
thrombosis and the plasma level of albumin. The objective
was to determine whether the physical chemical binding
coefﬁcient between albumin and FFA, measured by the
FFA/albumin molar ratio, regulated the rate of ﬁbrinogen
synthesis. A regulatory function could identify deﬁcient
albumin synthesis as the cause of increased synthesis and
turnover of ﬁbrinogen into occlusive ﬁbrin of coronary
thrombosis and thrombotic stroke.
Methods
Plasma Specimens
Human plasma samples were obtained from 53 male
Caucasian subjects between 20 and 70 years of age who
were diagnosed as clinically normal. Pathological plasma
samples were obtained from 29 male Caucasian patients
between 30 and 70 years of age with diagnosis of having
recovered from myocardial infarction or thrombotic stroke
with no evidence of other disease. Plasma was assayed for
albumin and non esteriﬁed or free fatty acids (FFA). Blood
was withdrawn after an overnight fast of 12 h or more. The
minimum requirements for accepting a patient as having
coronary heart disease or thrombotic stroke were (a) a
clinical and laboratory history of myocardial infarction or
thrombotic stroke, and (b) electrocardiographic or neuro-
logical and electroencephalographic change characteristic
of an infarction or thrombotic stroke. All donors were free
of drug therapy for a period of 6 weeks prior to blood
sampling. Anticoagulant consisted of 0.75 ml of 6.4% tri-
sodium citrate per 15 ml of blood.
Albumin Assay-Electrophoretic
Isolation of plasma albumin was processed in the Durrum
paper electrophoresis cell. The isolated albumin band was
stained, eluted and quantitated spectrophotometrically. The
method is described in the Beckman Technical Bulletin
No. TB6O5OA, Procedure B. Each sample was run in
triplicate.
Free Fatty Acid (FFA) Assay
FFA was extracted from plasma, titrated, and measured
according to the method of Dole and Meinertz (1960) and
conﬁrmed by gas chromatography (Beckman GC-4) on
diethylene succinate using reference standards.
Measure of Fibrinogen Synthesis
Methods for isolation and measure of plasma ﬁbrinogen
and the speciﬁcity of these methods have been published
(Pilgeram 1961, 1968; Pilgeram and Pickart 1967).
FFA Extracted Albumin
Human albumin, Cohn’s Fraction V (Bayer, Berkeley,
CA), 5% in 0.85 g% saline, was precipitated in an equal
volume of 10% trichloracetic acid. The precipitate was
centrifuged (1,000g for 10 min), extracted into 95% etha-
nol (ethanol volume: 10 9 original albumin volume), then
centrifuged 5,000g for 30 min. The supernatant ethanol
solution is poured slowly into 0C ether, then dried under
vacuum. The dried albumin was re-dissolved in distilled
water, dialyzed, and then lyophilized. This procedure
reduced the molar ratio of FFA/albumin from 1.16 to 0.13
measured by gas chromatography. Albumin electrophoretic
pattern and resolution were not altered by this procedure.
In Vitro Hepatocyte Synthesis of Fibrinogen
Human hepatocytes, 100 mg, were incubated for 2 h at 378
C in 2 ml of human plasma and 5 micro Curies of glycine-
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coagulant at the concentration of 1 mg/ml of incubation
media. Gas mixture of incubation ﬂask was 95% 02:5%
CO2. After incubation, the liver cells and bathing media are
centrifuged at 25,000g for 20 min. Fibrinogen was pre-
cipitated with 25% ammonium sulphate before being
converted to ﬁbrin and measure of radio activity. Hepato-
cytes were obtained from liver biopsies during cholecys-
tectomy on patients free of jaundice. The biopsy sample was
immediately placed in bicarbonate buffer (pH 7.4, 0–1C).
Cells were washed in buffer until no tricholoracetic acid
inducible turbidity occurred, then weighed.
Results
Analysis of the FFA/Albumin Ratio as a Function
of Thrombosis and Aging
Table 1 provides data with respect to the FFA/albumin
ratio in 92 normal subjects and patients who incurred
coronary thrombosis or thrombotic stroke. The ratio was
found to increase in association with increase in age of the
normal subject. The patient with thrombosis incurred an
increase in addition to the increase imposed by aging. No
signiﬁcant difference appeared between data obtained in
coronary thrombosis versus thrombotic stroke patients. The
increase in the patient is independent of the increase
associated with aging until the 60–70 year age group when
magnitude of the ratio in the normal subject enters into the
range associated with occurrence of a thrombotic event.
Groups of patients and normal subjects matched for age
show that patients exhibit signiﬁcant increase above the
normal subjects until reaching the 7th decade of life.
Comparison of the progressive increase in the FFA/albu-
min ratio of the patients to the base line of normal subjects
in the 20–30 year age group exhibits an increase of 35.3,
42.9, 46.5 and 47.8% respectively for the age groups of
30–40, 40–50, 50–60, and 60–70 years. The difference in
the FFA/albumin ratio between normal subjects and
patients declines with increasing age. By age 60–70 years,
the clinically normal subjects have attained a ratio which is
34.8% greater than the ratio found for age 20–30 years.
However, the 30–40 year old patient group has already
attained a 35.3% increase above the ratio in the normal
20–30 year age group and displays a ratio slightly greater
thantheratiofoundinthenormalsubjectinthe7thdecadeof
life. The 60–70 year old patient shows a 47.8% increase in
the ratio above that found in the normal 20–30 year group.
In summary, the FFA/albumin ratio is signiﬁcantly
increased in the patient with thrombosis and super imposes
on the patient an increase in addition to the progressive
increase occurring as a function of the aging process,
Fig. 1. By age 60–70 the clinically normal subject has
incurred an increase in the ratio of 34.8% which closely
approaches the 35.3% increase exhibited by the 30–40 year
age group of patients thus identifying a FFA/albumin ratio
of 1.12 as a threshold associated with susceptibility to risk
of thrombotic events.
Plasma Albumin Concentration as a Function
of Thrombosis and Aging
The plasma concentration of albumin decreases with
increasing chronological age and exhibits a further
decrease in the thrombosis patient in addition to the
decrease associated with aging, Fig. 2. Example is illus-
trated by comparing the plasma level in the 60–70 year
normal group to the 30–40 year age group of thrombosis
patients.
Plasma FFA Concentration as a Function
of Thrombosis and Aging
The plasma level of FFA progressively increases with
chronological age in the normal male Caucasian subject
and exhibits an increase in the thrombosis patient in
addition to the increase found in aging, Fig. 3. This change,
the reverse of that observed for albumin, shows the FFA
plasma level of the 30–40 and the 40–50 year old patient
groups to have increased to the level observed in the 50–60
and 60–70 year age group of normal subjects.
In Vitro Induction of Increased Fibrinogen Synthesis
by Hepatocytes Incubated in Patient Plasma Exhibiting
Elevated FFA/Albumin Ratios
Incubation of 100 mg of human hepatocytes for 2 h at
37C in 2 ml of plasma derived from patients with either
coronary thrombosis or thrombotic stroke induced a sig-
niﬁcant increase in the synthesis of ﬁbrinogen measured by
incorporation of the amino acid glycine-C14 into the pro-
tein structure, Fig. 4. An average FFA/albumin molar ratio
of 1.224, found in the 60–70 year old patient group,
induced a 235% increase above the FFA/albumin molar
ratio of 0.828 found in the 20–30 year old group of normal
subjects.
Regeneration of a Normal Rate of Fibrinogen Synthesis
in Human Hepatocytes by Restoration of a Normal
FFA/Albumin Molar Ratio in Plasma of Patients
Restoration of a young normal plasma albumin level in
patient’s plasma bearing the designated decrease in the
FFA/albumin molar ratio induced a progressive decline in
ﬁbrinogen synthesis to a normal physiological rate, Fig. 4.
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rate studies with an average deviation of 3.4%.
The converse of this study, based on murine hepato-
cytes, demonstrated that addition of Na-palmitate at a level
equivalent to the maximum observed difference in the FFA
level between fasted young normal male human subjects
and older patients induced over a 2 fold increase in the
uptake of glycine-Cl4 into ﬁbrinogen (Pilgeram and Pickart
1968). This study showed the causal factor to be speciﬁc
for the FFA/albumin ratio because the plasma albumin
level was maintained at a normal level in presence of
increases in the ratio. The current study employed albumin
as the variable controlling the ratio.
Table 1 FFA/albumin ratio as a function of aging and thrombosis
Normal subjects Molar ratio Percent increase Thrombosis patients Molar ratio Percent increase
Age group Age (years) FFA/albumin From age Group I Age group Age (years) FFA/albumin From age Group I
1 20–30 0.828 –
2 30–40 0.900 8.7 2 30–40 1.120 35.3
3 40–50 0.984 18.8 3 40–50 1.184 42.9
4 50–60 1.026 23.9 4 50–60 1.213 46.5
5 60–70 1.116 34.8 5 60–70 1.224 47.8
All values signiﬁcant at P\0.001
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Fig. 1 FFA/albumin ratio as a function of thrombosis and aging
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Fig. 2 Plasma albumin levels as a function of thrombosis and aging
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Fig. 3 Plasma FFA as a function of thrombosis and aging
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Fig. 4 Regeneration of normal ﬁbrinogen synthesis in human
hepatocytes by reduction of the FFA/albumin molar ratio in
plasma of patients with thrombosis. SA: speciﬁc activity ﬁbrin
(counts/min/mg)
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123Discussion
Biochemical interaction between albumin and fatty acids
has been well documented not only by albumin serving as
the obligatory cofactor for lipoprotein lipase correction of
the deﬁciency in clearing of alimentary lipemia in plasma
of patients with coronary artery disease (Pilgeram 1958;
Pilgeram et al. 1964) but also by studies which demon-
strated the physical chemical interaction between albumin
and fatty acids including the effect of fatty acid salts and
anions on albumin (Ballou et al. 1945; Goodman 1958). All
of these studies document the occurrence of albumin FFA
receptors which play signiﬁcant roles in physiological
chemical homeostasis of the living organism. The current
study sought to test whether the numerical molar ratio of
FFA to albumin could measure the strength of the physical
chemical binding coefﬁcient and whether this ratio served
as a molecular switch or mechanism controlling the degree
to which FFA controlled the rate of synthesis and turnover
of ﬁbrinogen into occlusive ﬁbrin.
The data in this study provide evidence that the ratio
serves as a measure of free fatty acid versus albumin bound
fatty acid. An increasing FFA/albumin ratio measures a
declining magnitude of association or binding between the
protein and fatty acid. A decreasing ratio measures
increasing strength of the binding coefﬁcient or less dis-
sociation or availability of FFA to enter into biochemical
reactions independent of albumin. The differential in the
binding coefﬁcient provides the basis for the FFA/albumin
ratio functioning as a mechanism or molecular switch
which determines direction and magnitude of two opposing
FFA biochemical pathways.
Reduction of the FFA/albumin ratio from 1.2 down to
0.8 is associated with an increased strength of the associ-
ation coefﬁcient between albumin FFA receptors and FFA
which, while reducing FFA activation of ﬁbrinogen syn-
thesis and turnover, activates an opposing fatty acid path-
way where albumin transports FFA to the mitochondrial
locus of oxidative energy metabolism utilizing FFA as the
substrate for generation of acetyl Co-A and oxidative
energy metabolism via the citric acid cycle and oxidative
phosphorylation. A beginning phase of this pathway has
been described in the study where plasma albumin was
discovered as the obligatory co-factor receptor of fatty
acids released by the action of lipoprotein lipase in cor-
rection of the alimentary lipemia clearing deﬁciency found
in male patients who had incurred coronary thrombosis
(Pilgeram 1958; Pilgeram et al. 1964). This albumin bound
FFA, labeled with C14, is transported to mitochondrial
oxidative energy metabolism demonstrated by prompt
appearance of C14 labeled CO2 (McCalla et al. 1957).
The function of this differential is demonstrated in the
current study where downloading albumin with FFA to a
ratio of 0.8 returned synthesis of ﬁbrinogen to a normal
physiological level consistent with a state of homeostasis
or a steady state. Uploading albumin with FFA to a molar
ratio of 1.2 weakens the binding coefﬁcient between
albumin and FFA resulting in increased levels of unbound
or free fatty acids which induced increased synthesis of
ﬁbrinogen to a level found in the plasma of patients who
incurred coronary thrombosis or thrombotic stroke (Pilge-
ram et al. 1973; Pilgeram 1973) or the development and
evolution of plaques or atheroma (Duguid 1946, 1949).
FFA, dissociated from albumin binding, has been dem-
onstrated to activate Hageman Factor (Didisheim and
Mibashan 1963) which activates the cascade sequence of
reactions which generate thrombin and its conversion of its
natural substrate ﬁbrinogen to the ﬁbrin thrombus. Intra
venous infusion of FFA into test animals with a vasculature
free of plaques and atheroma promptly induced massive
occlusive ﬁbrin thrombi (Connor et al. 1963). In an envi-
ronmental situation analogous to the human experience
where an increased incidence of heart attacks occur during
periods of stress, it was found that in vivo mobilization of
lipid from adipose tissue fat stores generated ﬁbrin thrombi
in normal test animals (Hoak et al. 1963).
A 520% (P\0.001) increase in circulating ﬁbrin
monomers and polymers was measured in the plasma of
ischemic thrombotic cerebrovascular disease (Pilgeram
et al. 1973; Pilgeram 1973). These patients exhibited
increased plasma levels of ﬁbrinogen and increased gen-
eration of thrombin. Monitoring the plasma level of
ﬁbrinogen, circulating ﬁbrin and generation of thrombin in
patients who had incurred and recovered from prior
ischemic events, e.g., TIA’s, demonstrated progressive
increase in plasma levels up to 16 days at which time
clinically overt events of thrombotic icti occurred (Pilge-
ram 1984). The progressive level and the magnitude of this
increase in the intra and extra vascular pool over a 16 day
time sequence preceding each icti precluded ulceration of a
plaque and procoagulant release as the cause of these
thrombotic events.
It has not escaped notice that a regulatory mechanism
based on a mathematical ratio between lipid and protein,
which determines direction and magnitude of biochemical
reactions in the systems biology of the life process, may
provide insight into the nature of the highly conserved
primordial evolutionary mechanism which controls aging
where acceleration of the mechanism induces the major
disease afﬂicting the human organism.
Manifestation of this control mechanism at the highest
possible level of physiological or evolutionary organization
based on two of the three main family groups of organic
molecules, protein versus lipid, is indicative of the primacy
of this code in evolutionary development of the life process
and the aging mechanism.
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